Some antidepressants could potentially be used to treat a wide range of diseases caused by bacteria living within cells, according to work by researchers in the Virginia Commonwealth University School of Medicine and collaborators at other institutions.
Research published in the April print edition of the journal Life Science Alliance, shows that antidepressant drugs called FIASMAs, including desipramine, amitriptyline, and nortriptyline, halt the growth or kill four different intracellular bacterial pathogens in tissue cell culture and animal models.
“Antibiotic options for diseases caused by intracellular bacteria are limited because many of these drugs cannot penetrate our cell membranes. In essence, the bacteria are protected,” said Jason Carlyon, Ph.D., leader of the study and professor in the VCU Department of Microbiology and Immunology.
Tetracycline antibiotics are most commonly prescribed to treat intracellular bacterial infections because they can cross cell membranes to reach the microbes. However, tetracyclines can cause allergic reactions in some patients and physicians advise against their use by pregnant women and children due to undesirable side effects. Additionally, antibiotic resistance in some intracellular bacteria has been reported.
“It would be highly beneficial to have a class of drugs to treat such diseases in patients for whom tetracyclines are contraindicated,” Carlyon said. “These drugs could provide an alternative to antibiotics or even be used in conjunction with them as an augmentation approach to treat infections that typically require prolonged courses of antibiotic therapy, such as those caused by Chlamydia pneumoniae and Coxiella burnetti.”
The team of researchers from VCU, Indiana University Medical Center, University of Nebraska Medical Center, University of Arkansas for Medical Sciences, and the University of South Florida, including Carlyon and lead author Chelsea Cockburn, an M.D.-Ph.D. candidate, are the first to investigate the mechanisms by which FIASMAs target multiple intracellular bacteria in detail.
The scientists tested FIASMA susceptibility for four bacterial species that cause human granulocytic anaplasmosis, a tick-borne disease that attacks white blood cells called neutrophils and can be fatal to immune compromised individuals; Q fever, a debilitating pneumonic disease; and two chlamydia infections.
FIASMAs ultimately disrupt how cholesterol, a key nutrient utilized by many intracellular pathogens, traffics inside cells to alter bacterial access to the lipid. The researchers first proved FIASMA treatment efficacy by halting anaplasmosis in both tissue culture and mice. Next, they extended their observations to demonstrate that FIASMA treatment killed the Q fever agent,Coxiella burnetii, and partially inhibited chlamydial infections in cell culture.
“Since FIASMAs influence cholesterol trafficking in the cell and cholesterol plays a role in so many facets of our biology, they have been used to treat a wide variety of conditions and diseases,” Carlyon said.
He added that the effect of FIASMAs on intracellular cholesterol ultimately bypasses the need to directly target the bacteria.
“What is so exciting about this study is that the class of drugs we evaluated targets an enzyme in our cells regulating cholesterol, not the bacteria,” Carlyon said. “I do not envision the pathogens being able to develop resistance to this treatment because it is targeting a host pathway that they very much need to grow and survive inside of the body.”
The Latest on: Alternative to antibiotics
via Google News
The Latest on: Alternative to antibiotics
- New Book: "Antibiotics: What Everyone Needs to Know"on June 25, 2019 at 2:58 am
but also the research that could reveal a new generation of viable antibiotics or creative alternatives. The result is a book that finds hope among ever-morphing bacteria — and a seemingly ... […]
- How to make the healthiest, most ethical and sustainable food choices if you eat meat, dairy, and eggson June 21, 2019 at 12:03 pm
Others say that it’s unrealistic to think everyone will give up animal products completely—even with all the amazing alternative options out there ... to the environment [as well as] hormones and ... […]
- Engineered probiotic designed to provide antibiotic alternativeon June 21, 2019 at 12:03 am
Pando Nutrition is looking to provide an antibiotic alternative to poultry producers by genetically engineering a probiotic-enrobed enzyme, says CEO. The California-based feed additive startup is ... […]
- Antibiotic treatment and flares of rheumatoid arthritis: a self-controlled case series study analysis using CPRD GOLDon June 20, 2019 at 2:48 am
An alternative theory is that sulphonamide and trimethoprim antibiotics are acting through another microbial trigger, as yet unidentified. This study has generated directions for future work. This ... […]
- Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New Yorkon June 18, 2019 at 4:01 am
... antibiotic resistance crisis and the urgent need for the development of new antibiotic alternatives. Dr. Schooley will be available to answer questions following the meeting. Armata's ... […]
- Fish Farms Face Threats To Growth Prospects From Climate Change And Antibiotics Overuseon June 17, 2019 at 7:05 am
However, the report also highlights a number of ways that companies in the sector are starting to tackle these challenges, including replacing antibiotics with probiotics, looking at alternatives to ... […]
- Experts: Sanitizers are good to useon June 17, 2019 at 6:02 am
“Primarily, they’re arising from the use of systemic antibiotics.” Michelle Barron ... Compared with soap and water, sanitizers are a convenient alternative when you’re on the go and can also be more ... […]
- GM's race to outflank Tesla may be stalling outon June 17, 2019 at 5:08 am
While national restaurant chains are racing to add alternative-meat options ... chicken raised without antibiotics, and milk from cows that have not been treated with artificial growth hormones. But ... […]
- Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Actionon June 17, 2019 at 5:00 am
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis ("OM”), today announces the ... […]
- Selective killing of antibiotic-resistant bacteria from withinon June 17, 2019 at 4:42 am
Although López-Igual and colleagues’ system will probably not immediately solve the problem of antibiotic-resistant cholera infections, it might make an important contribution to the arsenal of ... […]
via Bing News